INSTITUTI NAL

Ambuja Cements

Stellar show yet again; dividend bonanza announced

During 3QCY20, Ambuja Cements (ACEM) reported strong results. Standalone net sales/EBITDA/APAT rose 9/55/88% YoY to Rs 28.53/6.80/4.41bn respectively. Volumes jumped 8% YoY on strong retail demand. Opex fell 8% YoY on robust (and structural) cost controls and low fuel prices, driving a 44% jump in unitary EBITDA to Rs 1,200/MT. In a positive surprise, ACEM announced Rs 17/share dividends, thus paying off 60% of its large cash pile up on books. We maintain BUY with a higher target price (SOTP-based) of Rs 283/share, owing to increased volume growth and robust unitary EBITDA visibility, and a leaner balance sheet, post the large dividend payout.

- Strong 3QCY20 results, large dividend payout: Riding on robust retail demand in north, central and east markets, ACEM printed 8% YoY volume rise. NSR also remained solid at +1% YoY. Opex reduction accelerated to 8% YoY, benefitting from structural metrics (fixed cost controls, logistics optimization and Material Supply Agreement with ACC) and lower fuel prices. Thus, its unitary EBITDA soared 44% YoY to Rs 1,200/MT. It also announced Rs 17/share dividend (60% of its cash balance, 7% pre-tax yield).
- Outlook: Buoyed by structural opex reduction and healthy pricing, we expect ACEM's unitary EBITDA to rebound to a 13-year high of Rs 1,176/MT in CY20E and to sustain during CY21/22E. Its upcoming expansion in Rajasthan by 2QCY21 will boost volume growth during CY21-23E. We raise our EBITDA estimates for CY20/21/22E by 6/7/6% factoring in the cost controls benefits. Robust margin, high growth visibility and leaner balance sheet (large dividend payout) should drive rerating. We raise our valuation multiple for standalone business to 12x Sep'22E EBITDA (earlier 11x), inline its 10-year mean. We value its 50% holding in ACC at a 20% discount, thus leading to a SOTP target price of Rs 283/share with a BUY rating.

Standalone Quarterly/Annual Financial summary

YE Dec (Rs mn)	3Q CY20	3Q CY19	YoY (%)	2Q CY20	QoQ (%)	CY18	CY19	CY20E	CY21E	CY22E
Sales (mn MT)	5.7	5.3	7.8	4.2	35.3	24.2	24.0	22.5	25.3	27.5
NSR (Rs/MT)	5,031	4,992	0.8	5,195	(3.2)	4,697	4,870	4,997	5,040	5,111
Opex (Rs/MT)	3,831	4,156	(7.8)	3,775	1.5	3,913	3,973	3,821	3,881	3,951
EBITDA (Rs/MT)	1,200	836	43.5	1,421	(15.5)	784	897	1,176	1,158	1,160
Net Sales	28,525	26,258	8.6	21,768	31.0	113,568	116,679	112,680	127,277	140,695
EBITDA	6,803	4,398	54.7	5,952	14.3	18,953	21,489	26,524	29,253	31,927
APAT	4,405	2,346	87.8	4,534	(2.8)	12,129	14,770	18,199	19,635	20,807
AEPS (Rs)	2.2	1.2	87.8	2.3	(2.8)	6.1	7.4	9.2	9.9	10.5
EV/EBITDA (x)						18.6	15.8	13.5	12.0	10.4
EV/MT (Rs bn)						11.96	11.50	12.11	11.20	10.64
P/E (x)						41.6	34.1	27.7	25.7	24.2
RoE (%)						5.9	6.8	8.5	9.2	9.1

Source: Company, HSIE Research, Standalone Financials

Estimates revision

Rs Bn	CY20E	CY20E	Change	CY21E	CY21E	Change	CY22E	CY22E	Change
	Old	Revised	%	Old	Revised	%	Old	Revised	%
Net Sales	109.8	112.7	2.6	124.0	127.3	2.6	137.1	140.7	2.6
EBITDA	24.9	26.5	6.4	27.4	29.3	6.9	30.0	31.9	6.3
APAT	16.2	18.2	12.6	17.4	19.6	12.7	19.3	20.8	7.7
AEPS (Rs)	8.1	9.2	12.6	8.8	9.9	12.7	9.7	10.5	7.7

Source: Company, HSIE Research

BUY

CMP (as on 22	Rs 254	
Target Price	Rs 283	
NIFTY		11,896
KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	Rs 260	Rs 283
EDITO A 0/	CY20E	CY21E
EBITDA %	6.4	6.9

KEY STOCK DATA

Bloomberg code	ACEM IN
No. of Shares (mn)	1,986
MCap (Rs bn) / (\$ mn)	504/6,838
6m avg traded value (Rs mn)	1,082
52 Week high / low	Rs 256/137

STOCK PERFORMANCE (%)

	3 M	6 M	12M
Absolute (%)	26.2	43.7	29.5
Relative (%)	19.1	14.4	25.4

SHAREHOLDING PATTERN (%)

	Jun-20	Sep-20
Promoters	63.27	63.27
FIs & Local MFs	13.60	13.29
FPIs	16.25	16.79
Public & Others	6.88	6.65
Pledged Shares	-	-
Source · BSE		

Pledged shares as % of total shares

Rajesh Ravi

rajesh.ravi@hdfcsec.com +91-22-6171-7352

Saurabh Dugar

saurabh.dugar@hdfcsec.com +91-22-6171-7353





Disclosure:

Authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

HDFC securities

Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com